FDA approves Avastin for platinum-resistant, recurrent ovarian cancer
the ONA take:
Roche has announced that the U.S. Food and Drug Administration (FDA) has approved Avastin (bevacizumab) for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in combination with pacltiaxel, pegylated liposomal doxorubicin, or topotecan.
The drug is indicated for patients who have received no more than 2 prior chemotherapy regimens. The recommended dose of this indication is bevacizumab 10mg/kg every 2 weeks in combination with one of the above intravenous chemotherapy regimens, or bevacizumab 15mg/kg every 3 weeks in combination with topotecan.
The approval by the FDA is based upon the randomized, open-label, multicenter, phase 3 AURELIA trial, which investigated bevacizumab plus chemotherapy versus chemotherapy alone in 361 patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer that recurred within 6 months from the most recent treatment with platinum-based therapy.
Patients had a median age of 61 years. Median progression-free survival was 6.8 months and 3.4 months for chemotherapy plus bevacizumab and chemotherapy alone, respectively (P < 0.0001). Overall survival was 16.6 months and 13.3 months for chemotherapy plus bevacizumab and chemotherapy alone. This FDA approval is the sixth indication for Avastin.
Avastin (bevacizumab) approved for treatment of platinum-resistant recurrent epithelial ovarian cancer.
Cancer drug Avastin is already enjoying wide acceptance in Europe after it was approved for use earlier in the year. The same could happen in the United States soon as the Food and Drug Administration recently approved the use of Avastin as a treatment option alongside chemotherapy in battling platinum-resistant, recurrent ovarian cancer. Roche announced the approval Monday, based on results from a Phase III AURELIA study showing that using Avastin in combination with chemotherapy cut risks of worsening or death by up to 62 percent in women who have platinum-resistant, recurrent ovarian cancer compared to those who underwent chemotherapy alone.
"Avastin plus chemotherapy is the first new treatment option for women with this difficult-to-treat type of ovarian cancer in more than 15 years," said Roche Global Product Development Head and chief medical officer, Sandra Horning, M.D.
- Immunotherapy May Benefit Some Patients with Papillary Thyroid Carcinoma
- Screening Recommendations for Children with Common Cancer Predisposition Syndromes
- Significance of Prostate Cancer Treatment-Related Factors Differ in Black, White Men
- New Study Questions Standard Dosage for Treating Metastatic Non-Small Cell Lung Cancer
- Superior Tolerability, Efficacy With Alectinib in Treatment-Naïve ALK-poistive NSCLC
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Lack of Transfusion Services a Barrier to Hospice Care for Patients With Blood Cancers
- Aspirin Use May Lower Breast Cancer Risk in Women with Diabetes
- Ethnic Differences, Cultural Barriers Negatively Impact Mammography Follow-up Among Asian Ethnic Groups
- Study Questions Safety of E-cigarettes vs Regular Tobacco Cigarettes
- Changes in Pulmonary Function Tests in Breast Carcinoma Patients Treated With Locoregional Post-mastectomy Radiotherapy: Results of a Pilot Study
- Increases in Liver Cancer Incidence Influenced by Higher Rates of Comorbidities
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|